Buyers eye Relypsa and its hyperkalemia drug

Eric Palmer Redwood City, CA-based Relypsa has hired an investment bank to check out M&A offers, Reuters reported. Relypsa isn't commenting but the news service says several ...

Harvard, Tufts med students stage protest at ‘biased’ $2.9B drug development figure

Ben Adams Around two dozen students from Harvard Medical School and Tufts University as well as members of health activist groups protested in front of the Tufts Center for the Study ...

Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcoma

Eric Palmer Japan's Eisai got a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced ...

Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen

John Carroll Genentech has moved to the head of a small group of players in the anti-inflammatory arena, bagging rights to an antibody that scrambles the connection between IL-33 and ...

Langer-backed biotech reboots with $38M, new name and new cancer drug tech

John Carroll Four-year-old biotech Blend Therapeutics, launched with the scientific backing of MIT's Robert Langer and colleagues, is jettisoning its one-time lead drug program ...

Galapagos’ bowel drug misses the mark in Phase II

Damian Garde Belgian biotech Galapagos is shutting down an ulcerative colitis program after its top prospect failed to make a difference in a Phase II trial, putting off plans for late-stage ...

GSK, AstraZeneca and J&J back $57M effort to springboard university drug research

John Carroll Three of the U.K.'s leading universities are joining hands with three of the world's biggest pharma giants to create a new translational medicine group aimed at ...

Shire gets back on track with once-rejected eye drug

Damian Garde Shire has resubmitted the once-rejected eye treatment lifitegrast for FDA approval, handing in new data the company hopes will get its self-described blockbuster drug onto ...

Shkreli’s 5th Amendment hall pass rejected for congressional drug pricing hearing

Emily Wasserman Pharma bro Martin Shkreli is requesting a hall pass to get out of testifying at a congressional hearing on drug pricing next week after receiving a subpoena ordering ...

GlaxoSmithKline bails on Basilea’s eczema drug, nixing a $72M payout

Damian Garde GlaxoSmithKline has abandoned its plot to win FDA approval for an eczema treatment from Basilea Pharmaceutica, ending a project that could have paid its partner about $ ...

Galapagos advances AbbVie-partnered CF drug; UCL forms £50M fund; Vasopharm bags €20M

Nick Paul Taylor In this week's EuroBiotech Report, the first of two correctors destined for use in Galapagos' triple-hit cystic fibrosis therapy is now in the clinic. With ...

UPDATED: Alkermes slammed as top depression drug fails two PhIIIs

John Carroll Alkermes reported this morning that its closely watched depression drug ALKS-5461 failed to hit the primary endpoints in the first two of three Phase III studies, slamming ...
Page 1 of 4512345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS